Skip to main content

Volume 13 - Issue 11 - November 2016

November 2016 Issue 11 Volume 13


Interview by Jennifer Ford

The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa agents in pe…

Interview by Jennifer Ford

The 1-year results from IN.PACT Global confirm safety and effectiveness of the In.Pact Admiral DCB in femoropopliteal lesions. Michael R. Jaff, DO, answers questions about the results and their implications for peripheral vascular therapy.
Case Report

Darren Ramoutar, DO; Vincent Varghese, DO
From Deborah Heart and Lung Center Interventional Cardiology and Endovascular Medicine, Browns Mills, New Jersey.

The authors present a rare case of upper extremity PCD related to the presence of a peripherally inserted central catheter. Endovascular therapy was utilized in the form of acoustic-assisted catheter directed thrombolysis with complete resolution of…
Clinical Review

Carly N. Richards, MD; Peter A. Schneider, MD

From the Division of Vascular Therapy, Kaiser Foundation Hospital and Department of Surgery, Tripler Army Medical Center, Honolulu, Hawaii

Limb salvage rates that are consistently superior to patency rates for CLI patients have prompted some to question whether perfusion really matters. The authors explore the discrepancy and find that the difference can be explained by several factors,…
Editor's Corner

Craig Walker, MD

The discrepancy between patency and limb salvage for patients with the most severe peripheral arterial disease has been the source of much debate. It is possible, however, that the discrepancy is not as wide as previously thought.
Back to Top